Metabotropic Glutamate 5 Receptor

A type I G protein-coupled receptor mostly expressed post-synaptic pyramidal cells of the cortex and CENTRAL NERVOUS SYSTEM.

Also Known As:

Receptor, Metabotropic Glutamate 5; Metabotropic Glutamate Receptor 5a; Metabotropic Glutamate Receptor 5b; mGluR5 Protein; mGluR5a Protein; mGluR5b Protein; Protein, mGluR5; Protein, mGluR5a; Protein, mGluR5b; Metabotropic Glutamate Receptor 5; Receptor 5, Metabotropic Glutamate

Networked: 276 relevant articles (7 outcomes, 32 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Membrane Proteins: 10078
    - Cell Surface Receptors: 2125
      - G-Protein-Coupled Receptors: 4701
        Metabotropic Glutamate Receptors: 1173
        Metabotropic Glutamate 5 Receptor: 276
        human GRM5 protein
        mouse Grm5 protein
        rat Grm5 protein
      - Neurotransmitter Receptors: 562
        Amino Acid Receptors: 25
        Glutamate Receptors: 2703
        Metabotropic Glutamate Receptors: 1173
        Metabotropic Glutamate 5 Receptor: 276
        human GRM5 protein
        mouse Grm5 protein
        rat Grm5 protein

Experts

1.	Zhang, Hong: 9 articles (10/2022 - 12/2015)
2.	Gu, Li: 8 articles (01/2021 - 12/2015)
3.	Hasler, Gregor: 8 articles (07/2020 - 07/2011)
4.	Treyer, Valerie: 8 articles (07/2020 - 07/2011)
5.	Ametamey, Simon M: 8 articles (01/2020 - 07/2011)
6.	Akkus, Funda: 7 articles (07/2020 - 01/2013)
7.	Matosin, Natalie: 7 articles (04/2018 - 03/2013)
8.	Lindemann, Lothar: 7 articles (01/2018 - 11/2011)
9.	Chung, Geehoon: 6 articles (12/2020 - 01/2017)
10.	Kim, Sang Jeong: 6 articles (12/2020 - 01/2017)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 07/01/2015 - "Environmental Enrichment Ameliorates Behavioral Impairments Modeling Schizophrenia in Mice Lacking Metabotropic Glutamate Receptor 5." 01/01/2022 - "In the present study, we used this neurodevelopmental model of schizophrenia to evaluate the therapeutic potential of positive allosteric modulation of metabotropic glutamate receptor 5 (mGluR5) during adolescence. " 01/01/2018 - "The objectives of this first-in-human study were to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, and maximum tolerated dose (MTD) of single ascending oral doses of RG7342, a positive allosteric modulator (PAM) of the metabotropic glutamate receptor 5 (mGlu5) for the treatment of schizophrenia, in healthy male subjects. " 01/01/2022 - "Combining the results of proteomic analyses with the known genes linked to schizophrenia revealed that metabotropic glutamate receptor 5 (mGluR5) was one of the miR-501-3p targets and was elevated in vivo upon loss of miR-501. " 11/06/2018 - "Touchscreen testing reveals clinically relevant cognitive abnormalities in a mouse model of schizophrenia lacking metabotropic glutamate receptor 5."
2.	Substance-Related Disorders (Drug Abuse) 03/01/2016 - "Selective negative allosteric modulators (NAMs) targeting the metabotropic glutamate receptor 5 (mGlu5) subtype are currently in clinical trials for the treatment of multiple neuropsychiatric disorders and have shown promise in preclinical models of substance abuse. " 03/01/2009 - "Accruing preclinical evidence about metabotropic glutamate 5 receptor antagonists as treatments for drug dependence highlights the irreplaceable contributions of animal studies to the discovery of new medications for human disorders." 11/01/2013 - "Negative allosteric modulators of metabotropic glutamate receptor 5 (mGlu5) have been actively pursued for over a decade as a potential treatment for anxiety, depression, substance abuse, pain, levodopa-induced dyskinesia in Parkinson's disease, fragile X Syndrome, autism, gastroesophageal reflux disease and lower-urinary-tract disorders. "
3.	Pain (Aches) 10/01/2021 - "We hypothesized that metabotropic glutamate receptor 5 (mGluR5) expressed in the nucleus accumbens (NAc) normalizes the depressive-like behaviors and pain following CSDS. " 12/07/2020 - "We found that the metabotropic glutamate receptor 5 (mGluR5) in the periaqueductal gray (PAG), the key area of endogenous pain modulation, is persistently active in normal conditions to maintain an appropriate sensory perception. " 01/01/2020 - "Metabotropic glutamate receptor 5 (mGluR5) has been reported to contribute to inflammatory pain. " 01/01/2019 - "Activation of metabotropic glutamate receptor 5 (mGluR5) specifically suppressed α1ins-mediated glycinergic transmission and evoked pain sensitization. " 01/01/2018 - "Metabotropic Glutamate Receptor 5 in the Medial Prefrontal Cortex as a Molecular Determinant of Pain and Ensuing Depression."
4.	Mental Disorders (Mental Disorder) 07/01/2015 - "Metabotropic glutamate receptor 5 (mGlu5) is a biological target implicated in major neurological and psychiatric disorders. " 01/01/2014 - "Metabotropic Glutamate Receptor 5 (mGluR5) negative allosteric modulators (NAMs) may play a role in some psychiatric disorders such as anxiety and depression. " 01/01/2017 - "Negative allosteric modulators (NAM) of metabotropic glutamate receptor 5 (mGluR5) have been implicated as a potential pharmacotherapy for a number of psychiatric diseases, including anxiety and depression. " 01/28/2014 - "Rethinking metabotropic glutamate receptor 5 pathological findings in psychiatric disorders: implications for the future of novel therapeutics." 01/01/2022 - "Metabotropic glutamate receptor 5 (mGluR5) has been implicated in stress-related psychiatric disorders, particularly major depressive disorder. "
5.	Traumatic Brain Injuries (Traumatic Brain Injury) 01/01/2017 - "Metabotropic glutamate receptor 5 deficiency inhibits neutrophil infiltration after traumatic brain injury in mice." 05/01/2015 - "Positive allosteric modulators (PAMs) of the metabotropic glutamate receptor 5 (mGluR5) are promising therapeutic agents for treating traumatic brain injury (TBI). " 06/29/2012 - "Expression and cell distribution of metabotropic glutamate receptor 5 in the rat cortex following traumatic brain injury." 01/01/2014 - "Recent studies show that neurodegeneration and neuroinflammation after traumatic brain injury can be inhibited as late as one month in animals by the activation of the metabotropic glutamate receptor 5 in microglia using (RS)-2-chloro-5- hydroxy-phenylglycine. " 06/01/2015 - "Positive allosteric modulators (PAMs) binding to the transmembrane (TM) domain of metabotropic glutamate receptor 5 (mGluR5) are promising therapeutic agents for psychiatric disorders and traumatic brain injury (TBI). "

Related Drugs and Biologics

1.	Glutamic Acid (Glutamate)
2.	mu Opioid Receptors (mu Opioid Receptor)
3.	Aminobutyrates (Aminobutyric Acid)
4.	Proteins (Proteins, Gene)
5.	Messenger RNA (mRNA)
6.	Oxidopamine (6 Hydroxydopamine)
7.	Fragile X Mental Retardation Protein
8.	Amyloid beta-Peptides
9.	norbin
10.	Rotenone

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Self Administration (Administration, Self)
4.	Analgesia